Valneva Reports H1 2026 Product Sales Of €64.0M Down From €91.0M YoY, Net Loss Widens To €63.3M From €20.8M YoY

Benzinga Earnings

Aug 13

Total product sales of €64.0 million
- In-line with expectations; full-year guidance of €135 -150 million reaffirmed
Solid cash position of €121.5 million as of end June 2026
- Reflects disciplined cash management and proceeds from the recent reserved offering1
- Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyond
Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2
- Pfizer remains optimistic about obtaining registration for the vaccine candidate3

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2659089138"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2659089138\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2659089138?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 13:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2659089138","market":"hk","top_or_hot":-1,"title":"Valneva Reports H1 2026 Product Sales Of €64.0M Down From €91.0M YoY, Net Loss Widens To €63.3M From €20.8M YoY","media":"Benzinga Earnings","content":"<html><body><ul><li>Total product sales of €64.0 million<ul><li>In-line with expectations; full-year guidance of €135 -150 million reaffirmed</li></ul></li><li>Solid cash position of €121.5 million as of end June 2026<ul><li>Reflects disciplined cash management and proceeds from the recent reserved offering1</li><li>Restructuring program implemented with positive P&amp;L and cash flow impacts expected in the second half of the year and beyond</li></ul></li><li>Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2  <ul><li>Pfizer remains optimistic about obtaining registration for the vaccine candidate3</li></ul></li></ul></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Valneva Reports H1 2026 Product Sales Of €64.0M Down From €91.0M YoY, Net Loss Widens To €63.3M From €20.8M YoY</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nValneva Reports H1 2026 Product Sales Of €64.0M Down From €91.0M YoY, Net Loss Widens To €63.3M From €20.8M YoY\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time\">2026-08-13 13:11</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><ul><li>Total product sales of €64.0 million<ul><li>In-line with expectations; full-year guidance of €135 -150 million reaffirmed</li></ul></li><li>Solid cash position of €121.5 million as of end June 2026<ul><li>Reflects disciplined cash management and proceeds from the recent reserved offering1</li><li>Restructuring program implemented with positive P&amp;L and cash flow impacts expected in the second half of the year and beyond</li></ul></li><li>Regulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2  <ul><li>Pfizer remains optimistic about obtaining registration for the vaccine candidate3</li></ul></li></ul></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.benzinga.com/news/earnings/26/08/61164467/valneva-reports-h1-2026-product-sales-64-0m-down-91-0m-yoy-net-loss-widens-63-3m-20-8m-yoy","article_id":"2659089138","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2659089138","pubTimestamp":1786597878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga Earnings","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"Total product sales of €64.0 millionIn-line with expectations; full-year guidance of €135 -150 million reaffirmedSolid cash position of €121.5 million as of end June 2026Reflects disciplined cash management and proceeds","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4539":"次新股","VALN":"Valneva SE"},"translate_title":"Valneva 报告 2026 年上半年产品销售额为 6400 万欧元，从同比 9100 万欧元下降，净亏损从同比 2080 万欧元扩大至 6330 万欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VALN":0.9},"content_text":"Total product sales of €64.0 millionIn-line with expectations; full-year guidance of €135 -150 million reaffirmedSolid cash position of €121.5 million as of end June 2026Reflects disciplined cash management and proceeds from the recent reserved offering1Restructuring program implemented with positive P&L and cash flow impacts expected in the second half of the year and beyondRegulatory decisions for Lyme disease vaccine candidate expected in the next twelve months2  Pfizer remains optimistic about obtaining registration for the vaccine candidate3","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,express","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}